Prism AI provides an AI-driven multi-omic data management and analytics platform that enables biotech companies and health systems to harness their data for drug development and biomarker discovery. This technology addresses the challenge of inefficient data utilization in creating effective therapies for complex diseases.
Funding
Funding not disclosed
Founders
Product
Problem
Biotech companies and health systems face challenges in efficiently managing and analyzing multi-omic data, hindering drug development and biomarker discovery for complex diseases. Inefficient data utilization slows down the creation of effective therapies.
Solution
Prism AI offers an AI-driven platform designed to manage and analyze clinical multi-omic data, enabling biotech companies and health systems to accelerate drug development and biomarker discovery. The platform unlocks the potential of existing data to create the next generation of drugs and biomarkers. By leveraging AI, Prism AI streamlines the process of data analysis, allowing for more effective cures for devastating diseases.
Target Audience
The primary customers are biotech companies and health systems seeking to improve their drug development and biomarker discovery processes.
Features
- AI-driven analytics for multi-omic data.
- Clinical data management tools.
- Platform designed for drug development.
- Platform designed for biomarker discovery.